UPDATE | September 11, 2026

Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma

  • MAIL

Samsung Bio waiting to break into peptides, nets 262M manufacturing deal with unnamed EU pharma


Samsung Biologics continues to build momentum through expanded manufacturing capabilities and strategic growth across emerging modalities.


The article highlights the company’s latest $262 million manufacturing agreement, alongside its growing global footprint and continued expansion into new areas of biopharmaceutical manufacturing.


Discover how Samsung Biologics is building for continued growth in a rapidly evolving biopharma landscape.


Samsung Bio waiting to break into peptides, nets 262M manufacturing deal with unnamed EU pharma


Samsung Biologics continues to build momentum through expanded manufacturing capabilities and strategic growth across emerging modalities.


The article highlights the company’s latest $262 million manufacturing agreement, alongside its growing global footprint and continued expansion into new areas of biopharmaceutical manufacturing.


Discover how Samsung Biologics is building for continued growth in a rapidly evolving biopharma landscape.

Share article

  • MAIL

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required